Persistent antibody depletion after rituximab in three children with autoimmune cytopenias.
We report 3 children who developed persistent antibody depletion and abnormal response to bacteriophage after rituximab treatment for autoimmune cytopenias. Whether these patients have developed immunodeficiency secondary to an underlying disease process, to rituximab, or both, is not understood. Rituximab is an efficacious drug for a number of pediatric conditions. However, some patients who receive the drug have prolonged suppression or absence of B-cell function. Families should be counseled of this possibility prior to therapy. Patients should have baseline measurement of quantitative immunoglobulins and specific antibody levels and should be monitored for long term changes in immune function after rituximab.
Adeli
Mehdi Mohammad G
MM
Duke University Medical Center, Durham, NC 277710, USA. mehdi.adeli@duke.edu
Eichner
Brian H
BH
Thornburg
Courtney
C
Williams
Larry
L
D000906:Antibodies / Q000097:blood / Q000187:drug effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D001327:Autoimmune Diseases / Q000150:complications / Q000188:drug therapy; D001435:Bacteriophages / Q000276:immunology; D002648:Child; D005260:Female; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000139:chemically induced*; D007165:Immunosuppression Therapy; D007223:Infant; D008297:Male; D010198:Pancytopenia / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D000069283:Rituximab
D000906:Antibodies; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab